BACKGROUND AND OBJECTIVES: IgG commonly co-exists with IgA in the glomerular mesangium of patients with IgA nephropathy (IgAN) with unclear clinical relevance. Autoantibody (autoAb) biomarkers to detect and track progression of IgAN are an unmet clinical need. The objective of the study was to identify IgA-specific autoAbs specific to IgAN. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: High-density protein microarrays were evaluated IgG autoAbs in the serum of IgAN patients (n = 22) and controls (n = 10). Clinical parameters, including annual GFR and urine protein measurements, were collected on all patients over 5 years. Bioinformatic data analysis was performed to select targets for further validation by immunohistochemistry (IHC). RESULTS: One hundred seventeen (1.4%) specific antibodies were increased in IgAN. Among the most significant were the autoAb to the Ig family of proteins. IgAN-specific autoAbs (approximately 50%) were mounted against proteins predominantly expressed in glomeruli and tubules, and selected candidates were verified by IHC. Receiver operating characteristic analysis of our study demonstrated that IgG autoAb levels (matriline 2, ubiquitin-conjugating enzyme E2W, DEAD box protein, and protein kinase D1) might be used in combination with 24-hour proteinuria to improve prediction of the progression of IgAN (area under the curve = 0.86, P = 0.02). CONCLUSIONS: IgAN is associated with elevated IgG autoAbs to multiple proteins in the kidney. This first analysis of the repertoire of autoAbs in IgAN identifies novel, immunogenic protein targets that are highly expressed in the kidney glomerulus and tubules that may bear relevance in the pathogenesis and progression of IgAN.
BACKGROUND AND OBJECTIVES: IgG commonly co-exists with IgA in the glomerular mesangium of patients with IgA nephropathy (IgAN) with unclear clinical relevance. Autoantibody (autoAb) biomarkers to detect and track progression of IgAN are an unmet clinical need. The objective of the study was to identify IgA-specific autoAbs specific to IgAN. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: High-density protein microarrays were evaluated IgG autoAbs in the serum of IgANpatients (n = 22) and controls (n = 10). Clinical parameters, including annual GFR and urine protein measurements, were collected on all patients over 5 years. Bioinformatic data analysis was performed to select targets for further validation by immunohistochemistry (IHC). RESULTS: One hundred seventeen (1.4%) specific antibodies were increased in IgAN. Among the most significant were the autoAb to the Ig family of proteins. IgAN-specific autoAbs (approximately 50%) were mounted against proteins predominantly expressed in glomeruli and tubules, and selected candidates were verified by IHC. Receiver operating characteristic analysis of our study demonstrated that IgG autoAb levels (matriline 2, ubiquitin-conjugating enzyme E2W, DEAD box protein, and protein kinase D1) might be used in combination with 24-hour proteinuria to improve prediction of the progression of IgAN (area under the curve = 0.86, P = 0.02). CONCLUSIONS:IgAN is associated with elevated IgG autoAbs to multiple proteins in the kidney. This first analysis of the repertoire of autoAbs in IgAN identifies novel, immunogenic protein targets that are highly expressed in the kidney glomerulus and tubules that may bear relevance in the pathogenesis and progression of IgAN.
Authors: Aniel J L Brambila-Tapia; Jorge I Gámez-Nava; Laura González-López; Lucila Sandoval-Ramírez; Julio Medína-Díaz; Montserrat Maldonado; Sergio R Gutierrez-Ureña; Gloria Martínez-Bonilla; Beatriz T Martín-Márquez; Mónica Vázquez Del Mercado; Arnulfo Nava-Zavala; José F Muñoz-Valle; Mario Salazar-Páramo; Ingrid P Dávalos-Rodríguez Journal: Rheumatol Int Date: 2010-03-24 Impact factor: 2.631
Authors: A Squarer; K V Lemley; S Ambalavanan; B Kristal; W M Deen; R Sibley; L Anderson; B D Myers Journal: J Am Soc Nephrol Date: 1998-08 Impact factor: 10.121
Authors: Magdalena Chechlinska; Jan Konrad Siwicki; Monika Gos; Malgorzata Oczko-Wojciechowska; Michal Jarzab; Aleksandra Pfeifer; Barbara Jarzab; Jan Steffen Journal: BMC Genomics Date: 2009-06-08 Impact factor: 3.969
Authors: Sang Hoon Woo; Tara K Sigdel; Van T Dinh; Minh-Thien Vu; Minnie M Sarwal; Richard A Lafayette Journal: Clin J Am Soc Nephrol Date: 2014-12-26 Impact factor: 8.237
Authors: Choli Hartono; Miriam Chung; Alan S Perlman; James M Chevalier; David Serur; Surya V Seshan; Thangamani Muthukumar Journal: Kidney Int Rep Date: 2018-03-11
Authors: Joshua Y C Yang; Reuben D Sarwal; Fernando C Fervenza; Minnie M Sarwal; Richard A Lafayette Journal: Int J Mol Sci Date: 2019-09-10 Impact factor: 5.923
Authors: Grégoire Couvrat-Desvergnes; Agathe Masseau; Olivier Benveniste; Alexandra Bruel; Baptiste Hervier; Jean-Marie Mussini; David Buob; Eric Hachulla; Philippe Rémy; Raymond Azar; Evelyne Mac Namara; Brigitte MacGregor; Laurent Daniel; Adeline Lacraz; Thomas De Broucker; Philippe Rouvier; Philippe Carli; Maurice Laville; Etienne Dantan; Mohamed Hamidou; Anne Moreau; Fadi Fakhouri Journal: Medicine (Baltimore) Date: 2014-01 Impact factor: 1.889